Drug Trial Radar · NCT06251947
Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen
Last checked: Nov 20, 2026Latest source record: May 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
83
Planned (sponsor's estimate)
Start
Apr 15, 2024
Primary completion
Jun 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Shandong UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- First posted
- Feb 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study was to observe the efficacy and safety of Efbemalenograstim Alfa in the prevention of absolute neutrophil count (ANC) reduction after chemotherapy in Ovarian and Cervical cancer patients at risk of platinum-containing chemotherapy with risk factors in febrile neutropenia (FN).
Conditions
- Ovarian Cancer
- Cervical Cancer
Interventions
Efbemalenograstim AlfaDrug
Efbemalenograstim Alfa is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of grade 3/4 neutropeniaTime frame: At the first of cycle 1 (each cycle is 21 days)
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Xiangya Hospital, Central South University,
Changsha, Hunan, China · Not yet recruiting
Zhongda Hospital, School of Medicine, Southeast University
Nanjing, Jiangsu, China · Not yet recruiting
Qilu Hospital of Shandong University
Jinan, Shandong, China · Recruiting
Qingdao Central Hospital, The Second Affiliated Hospital of Medical College of Qingdao University,
Qingdao, Shandong, China · Not yet recruiting
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, China · Not yet recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.